VIDEO: The Door-to-Unloading (DTU) STEMI Safety and Feasibility Trial
In 2009, the GuideLiner Catheter revolutionized the concept of guide extension, creating new possibilities in interventional cardiology. Now in its third generation, the GuideLiner V3 Catheter continues to build on a history of innovation and performance — one that has been demonstrated with more than half a million catheters in cath labs around the world.
Teleflex also offers a family of Turnpike Catheters. These contain a robust multi-layer shaft that provides impressive flexibility, torque and tracking over a 0.014” guidewire in complex coronary and peripheral interventions. The unique five-layer composite shaft provides an ideal combination of flexibility and torque response to help navigate through complex anatomy while the outer polymer layer paired with a 60 cm distal hydrophilic coating facilitates smooth catheter delivery. This portfolio consists of the Turnpike Catheter (standard version), the Turnpike Spiral Catheter, the Turnpike Gold Catheter, and the Turnpike LP Catheter. Each catheter configuration contains a specific design element to address various clinical challenges in complex procedures
This year, Teleflex acquired two well-known PTCA balloon catheters. The Chocolate XD PTCA Balloon Catheter is a specialty angioplasty balloon, used in the pre-dilatation and treatment of coronary lesions. The balloon’s proprietary nitinol constraining structure creates “pillows” and “grooves” that are designed to provide controlled dilatation while minimizing vessel wall trauma.
The Glider PTCA Balloon Catheter is a semi-compliant balloon with a skived tip and low entry profile. The tip design, coupled with hydrophilic coating and an innovative, torqueable shaft, allows for precise tip orientation for use in crossing complex lesions and stent struts.
For more information: www.teleflex.com
Akshay Khandelwal, M.D., director of medical operations at the Henry Ford Heart and Vascular Institute, Detroit, and associate professor of cardiology at Wayne State University, explains how his center has reduced X-ray radiation dose in the cardiac catheterization labs.
Watch the related VIDEO: Reducing Cath Lab Radiation Dose at Henry Ford Hospital — Discussion with Nicolas Bevins, Ph.D., vice chair, physics and research, and Jessica Harrington, RCIS, Henry Ford Hospital.
For more on how to reduce dose in the cath lan, read these related articles:
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic support with the Impella 2.5 heart pump during high-risk PCI can reduce the risk of AKI even when those patients had pre-existing kidney disease and a low ejection fraction. For more information: http://bit.ly/2Pfaqxh
Professor Ian Meredith, MBBS, Ph.D., global chief medical officer and executive vice president, Boston Scientific, explains key trial data presented at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference. He also explained the company's recent purchase of numerous start-up companies to expand in areas of structural heart, venous interventions, electrophysiology and oncology.
Hear Meredith's insights in the VIDEO: Future Research and Development Efforts in Cardiovascular Medicine
A discussion with Professor Ian Meredith, MBBS, Ph.D., global chief medical officer and executive vice president, Boston Scientific, on future directions for cardiology device technology development. He spoke to DAIC at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference.
Hear Meredith's insights in the VIDEO: Boston Scientific's Recent Cardiology Advances and Technology Acquisitions
DAIC Editor Dave Fornell takes a tour of some of the most innovative new cardiovascular technology he found on the expo floor at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference.
Here are links to other Editor's Choice videos at recent conferences:
Ashish Pershad, M.D., medical director, structural heart program, Banner University Medical Heart Institute, Phoenix, explains the difference he found between the FDA cleared Watchman left atrial appendage (LAA) occluder and the Abbott Amplatzer Amulet device now in U.S. trials. He spoke on these differences at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference.
Watch the VIDEO: New Data on LAA Occlusion From the PREVAIL and PROTECT Trials — Interview with Vivek Reddy, M.D.
Cindy Grines, M.D., chair and professor, department of cardiology, Zucker School of Medicine, Hostra/Northwell, spoke on this topic in sessions at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference.
Related Women's Heart Health Content:
VIDEO: Sex Differences in Diagnosing Heart Disease in Women — Interview with Doreen DeFaria Yeh, M.D.
VIDEO: How to Build a Successful Women’s Heart Center — Interview with Malissa Wood, M.D.
VIDEO: Creating a Cardio-Obstetrics Team — Doreen DeFaria Yeh, M.D.
Find more articles on women's heart issues in the Women's Cardiovascular Health channel
Nevin Kapur, M.D., FAHA, FACC, FSCAI, executive director, Cardiovascular Center for Research and Innovation, Tufts Medical Center, Boston, explains the importance of ventricular unloading in the management of acute myocardial infarction and cardiogenic shock. He spoke on this topic at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference.
Related Cardiogenic Shock Content:
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morristown Medical Center, part of Atlantic Health System, explains some of the technologies and techniques to close large vascular access sites due to TAVR, TEVAR and hemodynamic support devices. He was involved in a session on this topic at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference.
William Abraham, M.D., FACC, professor of medicine and director of the division of cardiovascular medicine, The Ohio State University Wexner Medical Center, explains the results of the late-breaking COAPT Trial at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference.
Ron Waksman, M.D., associate director of the division of cardiology and director of cardiovascular research and advanced education, Medstar Heart Institute, explains details of the late-breaking LRP (Lipid Rich Plaque) Trial at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference. The trial used near infrared spectroscopy (NIRS) combined with intravascular ultrasound (IVUS) to identify vulnerable plaques and track them over time to determine the accuracy of the risk assessment. He said this may be a paradigm shift for interventional cardiology, being able to identify high-risk lesions before they cause a heart attack.
There was a 77 percent increase in survival in cardiogenic shock patients treated using a new protocol in the National Cardiogenic Shock Initiative. The data was presented at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) meeting. The details are discussed here with Babar Basir, D.O., and William O'Neill, M.D., from Henry Ford Hospital.
Watch the related VIDEO: Overview of the National Cardiogenic Shock Initiative
Watch the related VIDEO: ‘j !Support Protocols at Henry Ford Hospital
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) database. Learn more at ProtectedPCI.com.
A discussion with Khaldoon Alaswad, M.D., director, cardiac catheterization lab, Henry Ford Hospital, on treating chronic total occlusions (CTOs) and other complex PCI cases. Watch the VIDEO: Treating Chronic Total Occlusions with Bill Lombardi, M.D., director of complex coronary artery interventions at the University of Washington. Read the article "How to Tackle Coronary CTOs."
A discussion with Nicolas Bevins, Ph.D., vice chair, physics and research, and Jessica Harrington, RCIS. They explain the use of shields, technique and use of newer angiography technologies to reduce X-ray radiation dose in the cardiac cath labs at Henry Ford Hospital, Detroit.
Watch the VIDEO: Technologies and Techniques to Reduce Radiation Dose in the Cardiac Cath Lab — Interview with Akshay Khandelwal, M.D., director of medical operations at the Henry Ford Heart and Vascular Institute
For more on how to reduce dose in the cath lan, read these related articles:
A discussion with William O’Neill, M.D., director of the Henry Ford structural heart program, Ruth Fisher, MBA, vice president of the program, and Janet Wyman, NP, program manager. Henry Ford Hospital has built a large, high-volume structural heart program that includes use of cutting edge new technologies and devices.
A discussion with William O'Neill, M.D., director of the structural heart program, Henry Ford Hospital, and Michele Voeltz, M.D., fellowship program director, interventional cardiology, explaining their process for selecting various levels of hemodynamic support.
Henry Ford Hospital also helped spearhead the Detroit Cardiogenic Shock Initiative that morphed into the National Cardiogenic Shock Initiative using these same protocols. Watch an interview with O'Neill explaining the national initiative.
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is deployed in coronary vessels. The vendor made its debute on the expo floor of the 2018 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting. The ABS system is in the process of obtaining regulatory approval and no products are currently for sale.
Behnam Tehrani, M.D., FSCAI, director of the cardiac cath lab, INOVA Heart and Vascular Institute, Fairfax, Va., discusses a complex, high-risk percutaneous coronary intervention (PCI) case where hemodynamic support from an Abiomed Impella device is used to support the patient.
Visit ProtectedPCI.com for more video cases. The website also has additional information on protocols for protected PCI and cardiogenic shock hemodynamic support.
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascular Hospital, Dallas, explains some of the key innovations his institution is using to improve cardiovascular care. These include the use of robotic percutaneous coronary intervention (PCI), FFR-CT imaging and transcatheter valve technologies.
Watch the VIDEO: Dedicated Cardiac MRI Use at the Baylor Scott White Heart Hospital — an interview with Haojie Wang, M.D., director of advanced cardiovascular MRI and a member of the heart valve clinic at Baylor Scott White Heart Hospital, Dallas.
Patrick Serruys, M.D., Ph.D., Imperial College London, explains where development of bioresorbable scaffolds stands in 2018. He spoke to DAIC at the Society of Cardiovascular Computed Tomography (SCCT) 2018 meeting.
Watch the related VIDEO What Went Wrong With the Absorb Stent?
Read the related article Current State of Bioresorbable Stent Technology
Read the related article Amaranth Unveils 85-micron Bioresorbable Stent
Kavitha Chinnaiyan, M.D., FACC, FSCCT, associate professor, Oakland University, William Beaumont School of Medicine, Royal Oak, Mich. She presented at the Society of Cardiovascular Computed Tomography (SCCT) 2018 meeting.
Related FFR-CT Content:
VIDEO: Implementation and the Science Behind FFR-CT — interview with James Min, M.D.
VIDEO: Early U.S. Experience With FFR-CT in Evaluating ED Chest Pain Presentation — interview with Simon Dixon, M.D.
VIDEO: Status of FFR-CT Adoption in the United States — interview with Campbell Rogers, M.D.
Jonathon Leipsic, M.D., FSCCT, professor of radiology and cardiology at the University of British Columbia, Vancouver, Canada, and an expert in transcatheter valve imaging. He spoke about his experiences with TAVR and TMVR trials and devices planning at the the Society of Cardiovascular Computed Tomography (SCCT) 2018 meeting.
An interview with Patrick Serruys, M.D., Ph.D., Imperial College London, principal investigator of the SYNTAX III Trial presented earlier this year as a late-breaker at EuroPCR. He presented the trial again at the Society of Cardiovascular Computed Tomography (SCCT) 2018 meeting.
Ori Ben-Yehuda, M.D., executive director of the Cardiovascular Research Foundation Clinical Trial Center, discusses the latest data from clinical trials focusing on transcatheter tricuspid valve repair (TTVR) technologies, at the 2018 Transcatheter Valve Therapies (TVT) annual meeting in Chicago.
Related Transcatheter Tricuspid Valve Content
DAIC Editor Dave Fornell highlights some of the most innovative new technology on the show floor of the American Society of Echocardiography (ASE) 2018 meeting. The segments include virtual reality workstations, advanced 3-D cardiac ultrasound quantification and visualization, improved echo-fluoro image fusion technology, and imaging aided by artificial intelligence.
Rebecca Hahn, M.D., professor of medicine and director of interventional echocardiography, Columbia University Medical Center, New York, explains that techniques for imaging the tricuspid valve, the advanced study of its disease etiology and the rapid development of transcatheter devices to treat tricuspid valve disease are all developing together. She spoke on these topics during sessions at both the American Society of Echocardiography (ASE) 2018 meeting and at the Transcatheter Valve Therapies (TVT) conference in June.
Related Transcatheter Tricuspid Valve Content:
Recent Advances in Transcatheter Valve Technology
VIDEO: Mitral and Tricuspid Valve Repair Technologies — interview with Azeem Latib, M.D.
VIDEO: Transcatheter Tricuspid Valve Repair and Replacement Technologies — interview with Rebecca Hahn, M.D.
This is a demonstration of the the Philips TrueVue photo-realistic rendering and lighting source technology. This example highlights a transcatheter ASD closure with two Amplatzer occluders. The technology allows users to changing the lighting conditions to improve contrast. The light source can also be moved around to change the shadows and add more depth perception. The light source also can be pushed through the tissue to back light the anatomical structures, as shown in this example at the American Society of Echocardiography (ASE) 2018 meeting. The backlighting confirms a gap at the top of the image where part of the septal defect remains exposed.
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have integrated. He also explains how incorporation of his suburban hospital with Northwestern’s Bluhm Cardiovascular Institute has enabled a new TAVR program.
Read the related article on this hospital, "Hospital Consolidation May Increase Access to TAVR, New Cardiac Technologies."
Northwestern Medicine has purchased several smaller Chicago suburban hospitals in the past few years to expand its healthcare system. This has enabled these smaller community hospitals to offer new, cutting-edge cardiovascular medical technologies much sooner than might have otherwise been possible due to its association with Northwestern Medicine's luminary Bluhm Cardiovascular Institute in Chicago. Central DuPage Hospital is one of the newer hospitals in the network and now offers transcatheter aortic valve replacements (TAVR), transcatheter leadless pacemakers, minimally invasive left atrial appendage (LAA) occlusions and the latest surgical valve replacement technologies.
Roxana Mehran, M.D., FACC, FACP, FCCP, FESC, FAHA, FSCAI, professor of medicine and director of interventional cardiovascular research and clinical trials at the Zena and Michael A. Wiener Cardiovascular Institute at Mount Sinai School of Medicine. She spoke on how to avoid acute kidney injury (AKI) and contrast-induced nephropathy (CIN) at the American College of Cardiology (ACC) 2018 meeting. Watch the VIDEO "How to Avoid Acute Kidney Injury in the Cath Lab," an interview with Hitinder Gurm, M.D.
A discussion with Ron Waksman, M.D., associate director of the division of cardiology and director of cardiovascular research and advanced education at MedStar Heart Institute, and professor of medicine (cardiology) at Georgetown University. He explained the ongoing clinical trials using near infrared spectroscopy to detect lipid rich plaque in the coronary arteries. He spoke to DAIC at the 2018 American College of Cardiology (ACC) meeting.
James Januzzi, M.D., Roman W. DeSanctis Endowed Distinguished Clinical Scholar in Medicine, and director of the Dennis and Marilyn Barry Fellowship in cardiology research at Massachusetts General Hospital, discusses the use of highly sensitive troponin testing for chest pain in the emergency department (ED). Read the related articles New Heart Attack Evaluation Cuts Unnecessary Tests, Time in ER and Highly-sensitive Troponin Test Can Detect Myocardial Injury After Non-Cardiac Surgery.
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at the 2018 meeting of the American College of Cardiology (ACC). Find links to other videos and the ACC 2018 Late-Breaking Trials.
Insights from the STS/ACC TVT Transcatheter Valve Registry, presented at the American College of Cardiology (ACC) 2018 meeting by Sammy Elmariah, M.D., MPH, interventional structural heart disease, Massachusetts General Hospital. See the following related content for other insights into transcatheter aortic valve replacement technology:
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer, University of Michigan Health System, at the 2018 American College of Cardiology (ACC) meeting. For more information, read the article "Understanding Contrast-Induced Nephropathy."
Watch the VIDEO "Strategies to Avoid Acute Kidney Injury Caused by Cath Lab Contrast," an interview with Roxana Mehran, M.D.
An economic analysis of the DEFINE-FLAIR study comparing FFR vs. iFR, found a cost savings of nearly $900. The late-breaking session was presented at the 2018 American College of Cardiology (ACC) meeting by Manesh Patel, M.D., investigator and member of the study steering committee, and chief, division of cardiology, Duke University. Read more about the economic study. Watch a VIDEO on the 2017 results of the DEFINE-FLAIR and SWED-HEART iFR vs. FFR trials.
The Zoll LifeVest is a temporary, wearable defibrillator designed as a safety net for patients, especially those being evaluated for a permanent implantable cardioverter defibrillator (ICD). The Vest Prevention of Early Sudden Death Trial (VEST), presented at ACC 2018, was the first randomized, controlled, multi-center trial of the wearable cardioverter defibrillator. It looked to see if this device could effectively reduce sudden death in patients who had recently suffered a heart attack and had reduced heart function. Read more about the VEST Trial.